Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2009

01.09.2009 | Melanomas

Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis

verfasst von: Alfredo A. Santillan, MD, MPH, Keith A. Delman, MD, Georgia M. Beasley, MD, Paul J. Mosca, MD, Steven N. Hochwald, MD, Stephen R. Grobmyer, MD, Robert H. Andtbacka, MD, R. Dirk Noyes, MD, John M. Kane, MD, Merrick I. Ross, MD, Douglas S. Tyler, MD, Jonathan S. Zager, MD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Isolated limb infusion (ILI) is a minimally invasive technique delivering regional chemotherapy to treat in-transit extremity melanoma. Determining perioperative factors that could predict toxicity is important to optimize strategies to improve clinical outcomes after regional chemotherapy in melanoma.

Methods

Perioperative factors from 171 ILI patients performed at eight centers from 2001 to 2008 were reviewed. The Wieberdink limb toxicity scale and creatine phosphokinase (CK) levels were used to measure toxicity. Logistic regression analysis was used to estimate the association between toxicity and perioperative parameters.

Results

Mild (grades I–II) and severe (grades ≥III) limb toxicity developed in 68% and 32% of patients, respectively. Melphalan adjusted for ideal body weight (aIBW) and papaverine were used in 47% and 63% of patients, respectively. Median peak CK for all patients was 563 U/l, and median peak occurred at postoperative day 4. On univariate analysis, papaverine and high CK levels (>563 U/l) were significantly associated with higher toxicity. On the contrary, aIBW was significantly associated with a lower risk of severe toxicity. Perfusate blood gas at 30 min [pH, PaO2, and base excess (BE) ], limb temperature, and ischemia time were not predictive of limb toxicity. On multivariate analysis, severe toxicity was associated with female sex (P = 0.01), papaverine (P = 0.01), and high peak CK levels (P < 0.01). Independent predictors of high CK levels included younger age, unadjusted melphalan dose, and low PaO2 at 30 min.

Conclusions

ILI can be performed with an acceptable morbidity. Papaverine use, female gender, and high peak CK were associated with higher limb toxicity. CK levels can be diminished significantly with aIBW.
Literatur
1.
Zurück zum Zitat Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol. 1999;6(3):315–21.PubMedCrossRef Borgstein PJ, Meijer S, van Diest PJ. Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol. 1999;6(3):315–21.PubMedCrossRef
2.
Zurück zum Zitat Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of intransit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12(8):587–96.PubMedCrossRef Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of intransit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12(8):587–96.PubMedCrossRef
3.
Zurück zum Zitat Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–48.PubMed Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–48.PubMed
4.
Zurück zum Zitat Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131–49; quiz 182–34.PubMedCrossRef Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131–49; quiz 182–34.PubMedCrossRef
5.
Zurück zum Zitat Gimbel MI, Delman KA, Zager JS. Therapy for unresectable recurrent and intransit extremity melanoma. Cancer Control. 2008;15(3):225–32.PubMed Gimbel MI, Delman KA, Zager JS. Therapy for unresectable recurrent and intransit extremity melanoma. Cancer Control. 2008;15(3):225–32.PubMed
6.
Zurück zum Zitat Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148(4):616–32.PubMedCrossRef Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148(4):616–32.PubMedCrossRef
7.
Zurück zum Zitat Minor DR, Allen RE, Alberts D, et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer. 1985;55(11):2638–44.PubMedCrossRef Minor DR, Allen RE, Alberts D, et al. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer. 1985;55(11):2638–44.PubMedCrossRef
8.
Zurück zum Zitat Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63(12):2551–61.PubMedCrossRef Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63(12):2551–61.PubMedCrossRef
9.
Zurück zum Zitat Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115(1):39–45.PubMed Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115(1):39–45.PubMed
10.
Zurück zum Zitat Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132(8):903–7.PubMed Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132(8):903–7.PubMed
11.
Zurück zum Zitat Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24(25):4196–201.PubMedCrossRef Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24(25):4196–201.PubMedCrossRef
12.
Zurück zum Zitat Moller MG, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008;24(3):275–89.PubMedCrossRef Moller MG, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008;24(3):275–89.PubMedCrossRef
13.
Zurück zum Zitat Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol. 2003;4(6):359–64.PubMedCrossRef Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol. 2003;4(6):359–64.PubMedCrossRef
14.
Zurück zum Zitat Hoven-Gondrie ML, Thijssens KM, Van den Dungen JJ, et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol. 2007;14(7):2105–12.PubMedCrossRef Hoven-Gondrie ML, Thijssens KM, Van den Dungen JJ, et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol. 2007;14(7):2105–12.PubMedCrossRef
15.
Zurück zum Zitat Eggimann P, Chiolero R, Chassot PG, et al. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest. 1995;107(4):1074–82.PubMedCrossRef Eggimann P, Chiolero R, Chassot PG, et al. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest. 1995;107(4):1074–82.PubMedCrossRef
16.
Zurück zum Zitat Grunhagen DJ, van Etten B, Brunstein F, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol. 2005;12(8):609–15.PubMedCrossRef Grunhagen DJ, van Etten B, Brunstein F, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol. 2005;12(8):609–15.PubMedCrossRef
17.
Zurück zum Zitat Vrouenraets BC, Keus RB, Nieweg OE, Kroon BB. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha ± interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol. 1997;65(2):88–94.PubMedCrossRef Vrouenraets BC, Keus RB, Nieweg OE, Kroon BB. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha ± interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol. 1997;65(2):88–94.PubMedCrossRef
18.
Zurück zum Zitat Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–92. Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–92.
19.
Zurück zum Zitat Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14(3):238–47.PubMedCrossRef Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14(3):238–47.PubMedCrossRef
20.
Zurück zum Zitat Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes Following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15(11):3003–13. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes Following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15(11):3003–13.
21.
Zurück zum Zitat Zager JS, Gershenwald JE, Aldrink EL, et al. Isolated limb infusion for locally recurrent and in-transit extremity melanoma: a combined institutional initial experience. Ann Surg Oncol. 2006;13(2):s84. Zager JS, Gershenwald JE, Aldrink EL, et al. Isolated limb infusion for locally recurrent and in-transit extremity melanoma: a combined institutional initial experience. Ann Surg Oncol. 2006;13(2):s84.
22.
Zurück zum Zitat Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13(8):1123–9.PubMedCrossRef Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13(8):1123–9.PubMedCrossRef
23.
Zurück zum Zitat Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195–205.PubMedCrossRef Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195–205.PubMedCrossRef
24.
Zurück zum Zitat Beasley GM, Caudle A, Petersen R, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the United States. J Am Coll Surg. 2009;In press. Beasley GM, Caudle A, Petersen R, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the United States. J Am Coll Surg. 2009;In press.
25.
Zurück zum Zitat Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9(2):127–36.PubMed Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9(2):127–36.PubMed
26.
Zurück zum Zitat Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18(10):905–10.PubMedCrossRef Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18(10):905–10.PubMedCrossRef
27.
Zurück zum Zitat Klaase JM, Kroon BB, van Geel BN, et al. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg. 1994;167(6):618–20.PubMedCrossRef Klaase JM, Kroon BB, van Geel BN, et al. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg. 1994;167(6):618–20.PubMedCrossRef
28.
Zurück zum Zitat Vrouenraets BC, Hart GA, Eggermont AM, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999;188(5):522–30.PubMedCrossRef Vrouenraets BC, Hart GA, Eggermont AM, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999;188(5):522–30.PubMedCrossRef
29.
Zurück zum Zitat Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994;4(Suppl 1):45–50.PubMed Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994;4(Suppl 1):45–50.PubMed
30.
Zurück zum Zitat Bonenkamp JJ, Thompson JF, de Wilt JH, et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol. 2004;30(10):1107–12.PubMedCrossRef Bonenkamp JJ, Thompson JF, de Wilt JH, et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol. 2004;30(10):1107–12.PubMedCrossRef
31.
Zurück zum Zitat Vrouenraets BC, Eggermont AM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27(4):390–5.PubMedCrossRef Vrouenraets BC, Eggermont AM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27(4):390–5.PubMedCrossRef
32.
Zurück zum Zitat Vrouenraets BC, Klaase JM, Kroon BB, et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg. 1995;130(1):43–7.PubMed Vrouenraets BC, Klaase JM, Kroon BB, et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg. 1995;130(1):43–7.PubMed
33.
Zurück zum Zitat Klaase JM, Kroon BB, Beijnen JH, van Slooten GW, van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70(1):151–3.PubMed Klaase JM, Kroon BB, Beijnen JH, van Slooten GW, van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70(1):151–3.PubMed
34.
Zurück zum Zitat Edwards MJ, Soong SJ, Boddie AW, Balch CM, McBride CM. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone. Arch Surg. 1990;125(3):317–21.PubMed Edwards MJ, Soong SJ, Boddie AW, Balch CM, McBride CM. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone. Arch Surg. 1990;125(3):317–21.PubMed
35.
Zurück zum Zitat Parsons PG, Carter FB, Morrison L, Regius Mary S. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res. 1981;41(4):1525–34.PubMed Parsons PG, Carter FB, Morrison L, Regius Mary S. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res. 1981;41(4):1525–34.PubMed
36.
Zurück zum Zitat Krementz ET, Carter RD, Sutherland CM, et al. Regional chemotherapy for melanoma. A 35-year experience. Ann Surg. 1994;220(4):520–34; discussion 534–25.PubMedCrossRef Krementz ET, Carter RD, Sutherland CM, et al. Regional chemotherapy for melanoma. A 35-year experience. Ann Surg. 1994;220(4):520–34; discussion 534–25.PubMedCrossRef
37.
Zurück zum Zitat Vrouenraets BC, Kroon BB, Klaase JM, et al. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol. 1997;4(1):88–94.PubMedCrossRef Vrouenraets BC, Kroon BB, Klaase JM, et al. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol. 1997;4(1):88–94.PubMedCrossRef
38.
Zurück zum Zitat Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion–comparison between the effects of perfusion with rhTNF alpha and a ‘triple-drug’ regimen. Eur J Cancer. 1997;33(4):596–601.PubMedCrossRef Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion–comparison between the effects of perfusion with rhTNF alpha and a ‘triple-drug’ regimen. Eur J Cancer. 1997;33(4):596–601.PubMedCrossRef
39.
Zurück zum Zitat Cheng TY, Grubbs E, Abdul-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg. 2003;186(5):460–7.PubMedCrossRef Cheng TY, Grubbs E, Abdul-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg. 2003;186(5):460–7.PubMedCrossRef
Metadaten
Titel
Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis
verfasst von
Alfredo A. Santillan, MD, MPH
Keith A. Delman, MD
Georgia M. Beasley, MD
Paul J. Mosca, MD
Steven N. Hochwald, MD
Stephen R. Grobmyer, MD
Robert H. Andtbacka, MD
R. Dirk Noyes, MD
John M. Kane, MD
Merrick I. Ross, MD
Douglas S. Tyler, MD
Jonathan S. Zager, MD, FACS
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0563-9

Weitere Artikel der Ausgabe 9/2009

Annals of Surgical Oncology 9/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.